|
|
|
Volumn 26, Issue 1 SUPPL. 3, 1999, Pages 22-25
|
|
What can be expected from the next generation of adjuvant breast cancer treatment?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE DERIVATIVE;
AROMATASE INHIBITOR;
BISPHOSPHONIC ACID DERIVATIVE;
CELL RECEPTOR;
CYCLOPHOSPHAMIDE;
DOCETAXEL;
DOXORUBICIN;
FLUOROURACIL;
METHOTREXATE;
MONOCLONAL ANTIBODY;
TAMOXIFEN;
TAXANE DERIVATIVE;
TUMOR MARKER;
ANGIOGENESIS;
APOPTOSIS;
ARTICLE;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER HORMONE THERAPY;
CLINICAL TRIAL;
GENE OVEREXPRESSION;
HUMAN;
ONCOGENE C ERB;
PRIORITY JOURNAL;
PROGNOSIS;
SIGNAL TRANSDUCTION;
ANIMALS;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CELL SURVIVAL;
CHEMOTHERAPY, ADJUVANT;
CLINICAL TRIALS;
DRUG SCREENING ASSAYS, ANTITUMOR;
HUMANS;
|
|
EID: 0032995225
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (4)
|
|
References (32)
|
